US Pharma MarketingThe post Corxel to advance oral obesity drug to Phase III trials appeared first on Clinical Trials Arena.
Corxel to advance oral obesity drug to Phase III trials
Corxel’s CX11, an oral GLP-1RA, led to weight loss of up to 11.5% in positive Phase II results in patients with obesity. Corxel’s CX11, an oral GLP-1RA, led to weight loss of up to 11.5% in positive Phase II results. The oral obesity drug market is set to reach $34.4bn in 2031, GlobalData analysis predicts. Credit: Artem Stepanov / Shutterstock.com Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a Phase II trial in the US, teeing it up for a pivotal trial. The New Jersey-based biopharmaceutical company said that in the Phase II trial (NCT07011797), CX11 – a oral small…
Corxel’s CX11, an oral GLP-1RA, led to weight loss of up to 11.5% in positive Phase II results in patients with obesity.
Source: Clinical Trials Arena